课题基金 / 基金详情

Analysis on the mechanism of survival, growth and differentiation of hematopoietic cells

Analysis on the mechanism of survival, growth and differentiation of hematopoietic cells
造血细胞存活、生长和分化机制分析
批准号:
14370302
负责人:
KANAKURA Yuzuru
金额:
$9.6万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

KANAKURA Yuzuru的其他基金

相似基金

相关文献

中文摘要
翻译
本研究从信号转导、转录调控、细胞周期调控和细胞凋亡等方面分析了造血细胞生长、分化和恶性转化的机制,得到如下结果:1.野生型和致癌型KIT(Asp 814 Val)KIT通过Tyrosine 719激活PI 3-K信号通路诱导细胞生长。2.野生型KIT通过Tyrosine 719和Tyrosine 567激活Src家族酪氨酸激酶和PI 3-K介导趋化性。增强介导细胞生长的Pim-2的表达,同时抑制PU.1和c/EBPa的表达,这两者都诱导粒细胞分化,从而促进未成熟骨髓细胞的生长并抑制其分化。4. Ras、STAT 5和PI 3-K之间的功能合作是BCR/ABL癌基因的完全致癌活性所必需的。5. PML抑制STAT 3活性,而其致癌形式PML/RAR α增强其活性。6.E2F1,G1/S转换的关键调节剂,通过特异性地抑制G1/S转换的NF-κ B活性而使宿主细胞对凋亡敏感。7.我们克隆了一种新的抗凋亡分子Anamorsin,8. Anamorsin基因敲除小鼠在妊娠晚期是胚胎致死性的,这是由于确定性造血
英文摘要
In this study, we have analyzed the mechanisms of growth, differentiation and malignant transformation of hematopoietic cells from the aspects of signal transduction, transcriptional regulation, cell cycle regulation and apoptosis and got the results as follows :1.Both wild-type KIT and oncogenic (Asp814Val) KIT induce cell growth by activating PI3-K signal pathway through Tyrosine719.2.Wild type KIT mediates chemotaxis by activating Src family tyrosine kinases and PI3-K through Tyrosine719 and Tyrosine567.3.Oncogenic FLT3 containing the internal tandem duplication (ITD) enhances the expression of Pim-2 that mediates cell growth, while it suppresses that of PU.1 and c/EBPa, both of which induce granulocytic differentiation, thereby enhancing the growth and inhibiting the differentiation of immature myeloid cells.4.Functional cooperation among Ras, STAT5, and PI3-K is required for full oncogenic activity of BCR/ABL oncogene.5.PML inhibits STAT3 activity, while its oncogenic form PML/RARa enhances its activity.6.E2F1, a critical regulator of Gl/S transition, sensitizes host cells to apoptosis by inhibiting NF-kB activity specifically at Gl/S transition.7.We have cloned a novel anti-apoptotic molecule Anamorsin, which reveals no homology to known apoptosis related molecules.8.Knockout mice for Anamorsin are embryonic lethal at late gestation due to the defect of definitive hematopoiesis.
期刊论文(157)
专著(0)
科研奖励(0)
会议论文
Matsumura, I. et al.: "Cell cycle regulation in hematopoietic stem cells."Res.Adv.in Blood. 2. 39-49 (2003)
Matsumura, I. 等人:“造血干细胞的细胞周期调节。”Res.Adv.in Blood。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Matsumura I, et al.: "Roles for E2F1 and c-Myc in the regulation of cell growth and survival"Cell Cycle. 2. 333-338 (2003)
Matsumura I 等人:“E2F1 和 c-Myc 在细胞生长和存活调节中的作用”细胞周期。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tanaka S, et al.: "Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome"Int.J.Mol.Med.. 12. 225-230 (2003)
Tanaka S,等:“慢性疲劳综合征中针对毒蕈碱胆碱能受体的自身抗体”Int.J.Mol.Med..12.225-230(2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
60
    Functional analysis of SATB1, a global transcription regulator, in hematopoietic stem cells
    • 批准号:
      16H05339
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2016
    • 负责人:
      KANAKURA Yuzuru
    • 依托单位:
    Analysis of the functions of anti-apoptotic molecule, Anamorsin -the roles in hematopoiesis and cellular iron metabolism-
    • 批准号:
      25293220
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.81万
    • 财政年份:
      2013
    • 负责人:
      KANAKURA Yuzuru
    • 依托单位:
    Screening of low molecular compounds, which inhibit cell proliferation and survival
    • 批准号:
      23659488
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      KANAKURA Yuzuru
    • 依托单位:
    Analysis of functions of anamorsin, an anti-apoptotic molecule, in hematopoiesis
    • 批准号:
      22390194
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2010
    • 负责人:
      KANAKURA Yuzuru
    • 依托单位:
    国内基金
    海外基金
    USP43-SAFB1轴调控FLT3突变急性髓系白血病细胞对FLT3抑制剂耐药的机制研究
    • 批准号:
      JCZRQNB202600664
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    靶向CASP1/GSDMD通路抑制FLT3突变阳性 AML患者耗竭性γ δ T细胞焦亡的机制研 究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      金真伊
    • 依托单位:
    FLT3调控结肠癌细胞膜MHCI稳定性的机制及干预策略研究
    • 批准号:
      D25H300004
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      丁玲
    • 依托单位:
    新型小分子FLT3抑制剂STI-8591在FLT3突变急性髓系白血病中的应用及机制研究
    • 批准号:
      MS25H080016
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      张仪
    • 依托单位: